Maureen Lane

Company: Curis Inc.

Job title: Vice President, Clinical Science

Seminars:

Spliceosome Mutations as a Surrogate Biomarker for Emavusertib Treatment in MDS and AML 2:55 pm

• Spliceosome mutations have previously been characterized as prognostic biomarkers in heme malignancies • Specific splicesome mutations drive expression of the IRAK4-L isoform which is oncogenic • Emavusertib is an IRAK4 inhibitorRead more

day: Day 1 - PM - red